The revolutionary BiVACOR heart device was moved to Phase 2 of FDA trials after success in five human patients.
A promising new mRNA-based vaccine for pancreatic cancer has shown potential in reducing the recurrence of the disease post-surgery. MSK's phase 1 cli ...
A Memorial Sloan Kettering phase 1 clinical trial revealed an immune response in some pancreatic cancer patients. Study ...
Interesting Engineering on MSN1d
New mRNA vaccine shows promise against pancreatic cancer, may extend life by 10 yearsIn a significant development for pancreatic cancer treatment, a phase 1 clinical trial has highlighted the potential of personalized mRNA vaccines to treat the deadly disease. This research comes at a ...
Further diversity was introduced by including trials from different disease areas. VAC18193RSV3006 was a randomised, double-blind, placebo-controlled, phase 3 trial to investigate the safety and ...
EQS-News: GeoVax, Inc. / Key word (s): Financial Mpox Clade 1 in the U.S. Highlights the Need for Vaccine Supply Diversification 19.02.2025 / 15:04 CET/CEST The issuer is solely responsible for the ...
A clinical trial from Memorial Sloan Kettering Cancer Center looked at the effects of a targeted mRNA vaccine on early-stage ...
Broad-Spectrum Antiviral NV-387 Phase II Clinical Trial Responding to MPox Pandemic in Africa, Readying to Tackle Bird Flu ...
The FDA has approved Bavarian Nordic’s Vimkunya, the first virus-like particle (VLP) chikungunya vaccine for patients over 12 years of age. According to the company, approval was based on strong ...
All nine patients treated with a personalized cancer vaccine following removal of their tumors remained cancer-free at a median data cut-off of 34.7 months.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback